Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident

被引:80
作者
Abraham, N. S.
El-Serag, H. B.
Hartman, C.
Richardson, P.
Deswal, A.
机构
[1] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1111/j.1365-2036.2007.03292.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim To assess degree of cyclooxygenase-2 (COX-2) selectivity of a non-steroidal anti-inflammatory drug (NSAID) and risk of myocardial infarction (MI) or cerebrovascular accident (CVA). Methods Prescription fill data were linked to medical records of a merged VA-Medicare dataset. NSAIDs were categorized by Cox-2 selectivity. Incidence of CVA and MI within 180 days of index prescription was assessed using Cox-proportional hazards models adjusted for gender, race, cardiovascular and pharmacological risk factors and propensity for prescription of highly COX-2 selective NSAIDs. Results Of 384 322 patients (97.5% men and 85.4% white), 79.4% were prescribed a poorly selective, 16.4% a moderately selective and 4.2% a highly selective NSAID. There were 985 incident cases of MI and 586 cases of CVA in > 145 870 person-years. Highly selective agents had the highest rate of MI (12.3 per 1000 person-years; [95% CI: 12.2-12.3]) and CVA (8.1 per 1000 person-years; [95% CI: 8.0-8.2]). Periods without NSAID exposure were associated with lowest risk. In adjusted models, highly selective COX-2 selective NSAIDs were associated with a 61% increase in CVA and a 47% increase in MI, when compared with poorly selective NSAIDs. Conclusions The risk of MI and CVA increases with any NSAID. Highly COX-2 selective NSAIDs confer the greatest risk.
引用
收藏
页码:913 / 924
页数:12
相关论文
共 58 条
[1]   Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription [J].
Abraham, NS ;
Cohen, DC ;
Rivers, B ;
Richardson, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (02) :299-306
[2]   National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs [J].
Abraham, NS ;
El-Serag, HB ;
Johnson, ML ;
Hartman, C ;
Richardson, P ;
Ray, WA ;
Smalley, W .
GASTROENTEROLOGY, 2005, 129 (04) :1171-1178
[3]   NSAIDs and gastrointestinal complications: new clinical challenges [J].
Abraham, NS ;
Graham, DY .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) :2681-2689
[4]  
Allison PD., 2010, SURVIVAL ANAL USING
[5]   Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke - A nested case-control study [J].
Andersohn, Frank ;
Schade, Rene ;
Suissa, Samy ;
Garbe, Edeltraut .
STROKE, 2006, 37 (07) :1725-1730
[6]   Risk of stroke associated with nonsteroidal anti-inflammatory drugs -: A nested case-control study [J].
Bak, S ;
Andersen, M ;
Tsiropoulos, I ;
Rodríguez, LAG ;
Hallas, J ;
Christensen, K ;
Gaist, D .
STROKE, 2003, 34 (02) :379-385
[7]   Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors [J].
Battistella, M ;
Mamdami, MM ;
Juurlink, DN ;
Rabeneck, L ;
Laupacis, A .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :189-192
[8]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]  
BRESALIER RS, 2005, N ENGL J MED
[10]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541